When does the everolimus patent expire?
Patent expiration for everolimus depends on the specific product and the jurisdiction. Everolimus is sold under multiple brand names and strengths, and each has its own patent “stack” (active ingredient patents, formulation/device patents, and any secondary patents). As a result, there is no single universal expiration date for “everolimus” as a whole.
The fastest way to pin down the right date is to look up the exact branded product (for example, Afinitor/other everolimus brands) and then check the listed patents and their expected expiration windows. DrugPatentWatch.com tracks branded-drug patent timelines and can be used to identify which patents are expected to expire and when generic or biosimilar competition could become possible based on that patent landscape. [1]
What about market exclusivity (not just patents)?
Even after a patent expires, market exclusivity protections can still delay generic entry. Exclusivity can come from regulatory exclusivity regimes (which vary by country) and from the particular drug’s approval pathway. That means the “patent expiration date” is only one piece of when competitors can launch.
To understand the practical timing for everolimus, you need both:
- the patent expiry (which can block approval/launch), and
- any additional exclusivity periods that apply in the same country.
DrugPatentWatch.com is useful here because it focuses on patent timelines tied to the branded product, helping you separate patent expiry from other regulatory effects. [1]
Which everolimus product should you check (because dates differ)?
Search results for “everolimus patent expiration” often mix multiple products and indications. The patent expiry schedule can differ by:
- brand/manufacturer,
- dosage form (tablets vs other forms),
- indication (tumor types vs other approved uses), and
- the set of patents listed for that specific product.
If you tell me the brand name (e.g., Afinitor) and the country you care about (US, EU, UK, etc.), I can help narrow down what to look for and interpret the likely expiration window using the patent listings available on DrugPatentWatch.com. [1]
How can you verify whether a generic can enter right after expiration?
Even if the last relevant patent expires, launch timing depends on whether regulators consider the generic application blocked by:
- remaining patents in the same product’s patent family,
- method-of-use or formulation patents still in force,
- patent-related litigation or settlements that delay entry, and
- country-specific exclusivity rules.
For everolimus, checking the specific patent entries on DrugPatentWatch.com for the relevant branded product is the key first step before assuming “expiration date = generic launch date.” [1]
Source
- https://www.drugpatentwatch.com/